Table 1 Differentially expressed cell surface antigens in three HNSCC cell lines, Detroit562, FaDu and BICR6 following treatment with radiation or cisplatin

From: CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma

 

Detroit562

FaDu

BICR6

Cell surface antigen

Control (%)

RT (%)

CDDP (%)

Control (%)

RT (%)

CDDP (%)

Control (%)

RT (%)

CDDP (%)

CD10

7.5

36.5

31.8

9.5

23.1

24.3

31.2

38.1

57.6

CD15s

40.7

52.6

66.8

25.5

95.6

74.2

58.4

65.5

78.3

CD146

64.5

76.8

89.2

19.6

82.9

37.3

3.7

9.2

15.2

CD282

8.6

26.7

27.6

11.5

98.8

14.3

7.1

25.3

30.3

  1. Abbreviations: CDDP, cisplatin; RT, radiotherapy.
  2. Control, no treatment; RT, cells were assayed 5 days after exposure to single fraction 8 Gy irradiation; CDDP, cells were assayed after exposure to 3 μ M cisplatin for 7 days. Data represent the percentages of each marker as measured by flow cytometry.
Back to article page